CN114557452A - Composition with liver and stomach protecting effects and preparation method and application thereof - Google Patents
Composition with liver and stomach protecting effects and preparation method and application thereof Download PDFInfo
- Publication number
- CN114557452A CN114557452A CN202210199923.9A CN202210199923A CN114557452A CN 114557452 A CN114557452 A CN 114557452A CN 202210199923 A CN202210199923 A CN 202210199923A CN 114557452 A CN114557452 A CN 114557452A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- composition
- weight
- lactalbumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 210000004185 liver Anatomy 0.000 title claims abstract description 39
- 210000002784 stomach Anatomy 0.000 title claims abstract description 27
- 230000002633 protecting effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 20
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 20
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 20
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- 102000004264 Osteopontin Human genes 0.000 claims abstract description 15
- 108010081689 Osteopontin Proteins 0.000 claims abstract description 15
- 235000020248 camel milk Nutrition 0.000 claims abstract description 14
- 108010067454 caseinomacropeptide Proteins 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 19
- 206010067125 Liver injury Diseases 0.000 claims description 16
- 235000013336 milk Nutrition 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 241000220317 Rosa Species 0.000 claims description 11
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 201000005917 gastric ulcer Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 231100000234 hepatic damage Toxicity 0.000 claims description 4
- 230000008818 liver damage Effects 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 230000003908 liver function Effects 0.000 abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 12
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000007958 sleep Effects 0.000 abstract description 4
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 34
- 108010024636 Glutathione Proteins 0.000 description 17
- 229960003180 glutathione Drugs 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 231100000753 hepatic injury Toxicity 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 108010046377 Whey Proteins Proteins 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 210000003097 mucus Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 235000021119 whey protein Nutrition 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- -1 oxygen free radical Chemical class 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007661 gastrointestinal function Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 102100040557 Osteopontin Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition with liver and stomach protecting effects and a preparation method and application thereof, and belongs to the technical field of health care products. The composition mainly comprises the following raw materials in parts by weight: 35-98 parts of alpha-lactalbumin, 0.5-40 parts of inulin, 0.5-10 parts of camel milk, 0.3-5 parts of osteopontin and casein glycomacropeptide. The composition can obviously improve liver function, enhance immunity and repair capability of organism, improve sleep, and increase toxin expelling and detoxifying function of organism; meanwhile, the composition can protect gastric mucosa and repair the damage of alcohol products and chemical products to the liver and gastric mucosa.
Description
Technical Field
The invention belongs to the technical field of health care products, and particularly relates to a composition with liver and stomach protecting effects, and a preparation method and application thereof.
Background
The liver is the largest gland of the human body and has very important and complex functions. The liver is the most highly metabolized organ of the human body, and can metabolize part of nutrients from the portal vein and remove toxic substances in the body. Thus, liver function disorders can cause abnormal metabolism in the body. The liver is the organ which participates in the most active metabolism of substances, has high demand on nutrients, and is the largest immune organ in the human body, contains abundant macrophages, and can phagocytose and remove harmful substances contained in blood, poisons absorbed by intestinal tracts, bacteria, residual medicines and the like. Chronic inflammation of the liver can be caused by long-term alcohol drinking, and insufficient intake of energy, protein and vitamins can cause malnutrition. Therefore, the function of the liver is kept normal, and the method has great significance for human health.
The stomach is the main digestive organ of the human body, with the prosperity and development of economy, the life rhythm of people is gradually accelerated, and gastrointestinal diseases such as gastritis and gastric ulcer also become important diseases affecting the health of the human body. The common symptoms of gastric ulcer are burning pain, flatulence, nausea and vomiting in the middle and upper part of the stomach, severe cases of gastric hemorrhage, severe pain in the middle and upper part of the stomach, weight loss, and excessive alcohol intake is one of the causes of gastric ulcer.
At present, the nutritional food and the health food for the liver and the intestines and the stomach are full of eyes, and the beverage, the oral liquid, the powder, the capsule, the tablet and the like are available on the market. According to market research and research data, most of the products are warm tonifying type traditional Chinese medicine products or nutritional meal replacement stomach nourishing type products, the nutrition mechanism is not clear, and the effect is easy to repeat.
Disclosure of Invention
The invention aims at the problems and provides a composition with the efficacy of protecting liver and stomach, a preparation method and application thereof. The composition can obviously improve liver function, enhance immunity and repair capability of organism, improve sleep, and increase toxin expelling and detoxifying function of organism; the composition can also protect gastric mucosa, and repair damage of alcohol products and chemical products to liver and gastric mucosa.
The invention is realized by the following technical scheme:
in a first aspect, the invention provides a composition with liver and stomach protecting efficacy, which mainly comprises the following raw materials in parts by weight:
35-98 parts of alpha-lactalbumin, 0.5-40 parts of inulin, 0.5-10 parts of camel milk, 0.3-5 parts of osteopontin and 0.3-4 parts of casein glycomacropeptide.
Further, in a preferred embodiment of the present invention, the composition mainly comprises the following raw materials in parts by weight:
40-95 parts of alpha-lactalbumin, 2-30 parts of inulin, 2-8 parts of camel milk, 0.5-2 parts of osteopontin and 0.5-2 parts of casein glycomacropeptide.
Further, in a preferred embodiment of the present invention, the composition mainly comprises the following raw materials in parts by weight:
90 parts of alpha-lactalbumin, 5 parts of inulin, 3 parts of camel milk, 1 part of osteopontin and 1 part of casein glycomacropeptide.
Further, in a preferred embodiment of the invention, the composition further comprises milk mineral salt and rose pollen.
Further, in a preferred embodiment of the present invention, the milk mineral salt is 0.2 to 3 parts by weight, and the rose pollen is 0.2 to 3 parts by weight.
In a preferred embodiment of the present invention, the milk mineral salt is 0.6 to 1.5 parts by weight, and the rose pollen is 0.2 to 1.5 parts by weight.
In a second aspect, the present invention provides a method for preparing the above composition, comprising:
mixing the alpha-lactalbumin, the inulin, the camel milk, the osteopontin and the casein glycomacropeptide according to the weight part.
Further, in a preferred embodiment of the present invention, the method further comprises the step of sieving the alpha-lactalbumin, inulin, camel milk, osteopontin and casein glycomacropeptide with a 60-80 mesh sieve before mixing.
Further, in a preferred embodiment of the present invention, the composition further comprises milk mineral salt and rose pollen.
In a third aspect, the invention provides an application of the composition in preparing a health-care product for preventing or treating liver injury and gastric ulcer.
Compared with the prior art, the invention has at least the following beneficial effects:
the composition provided by the invention has the functions of obviously improving liver functions, enhancing the immunity and the repair capability of organisms, improving sleep and increasing the functions of expelling toxin and detoxifying of the organisms; the composition can also protect gastric mucosa, and repair damage of alcohol products and chemical products to liver and gastric mucosa. The composition has protective effect on liver and stomach, is equivalent to an anti-ulcer medicament, has obvious effect on liver function repair and gastrointestinal function repair, and particularly has obvious effect on repairing fatty liver and gastrointestinal ulcer. In addition, the product is not easy to absorb moisture and agglomerate, has good taste, is convenient to eat, has reasonable price and has no toxic or side effect.
Detailed Description
Embodiments of the present invention will be described in detail with reference to the following examples, but those skilled in the art will understand that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the present invention, and that the specific conditions not specified in the examples are carried out according to conventional conditions or conditions suggested by the manufacturer, and that the reagents or equipment used are not specified by the manufacturer, and are all conventional products available through commercial purchase.
The technical scheme of the embodiment is as follows:
a composition with liver and stomach protecting effects mainly comprises the following raw materials in parts by weight:
35-98 parts of alpha-lactalbumin, 0.5-40 parts of inulin, 0.5-10 parts of camel milk, 0.3-5 parts of osteopontin and 0.3-4 parts of casein glycomacropeptide.
Further, the composition further comprises milk mineral salts and rose pollen.
Among them, alpha-lactalbumin is the most typical dietary tryptophan source, and serotonin (5-HT) is a neurotransmitter synthesized by tryptophan (Trp) and found primarily in the gastrointestinal and Central Nervous Systems (CNS). Serotonin content in the brain is involved in mood, alertness, sleep patterns, stress resistance, depression and appetite and is an important regulator of mood and appetite. The alpha-lactalbumin can ensure positive emotion and appetite while providing high-quality nutrition, and is an optimal solution for people with insufficient liver functions, particularly people with alcoholic liver diseases and chronic hepatitis. Meanwhile, cysteine provided by the alpha-lactalbumin is one of three essential amino acids for synthesizing glutathione. The rate of glutathione production depends on the intracellular cysteine content. Cysteine is a rate-limiting factor affecting glutathione synthesis, since the cysteine content in our diet is relatively insufficient and the part of cysteine containing sulfur molecules is the main reason for the biological activity of glutathione production.
Glutathione plays an important role in the human body as follows: (1) support the normal function of the immune system: during the course of the immune response, lymphocytes are constantly replicating and producing antibodies, and it is necessary to ensure adequate glutathione levels in lymphocytes. (2) Antioxidant free radical scavenger: glutathione plays an extremely important role in combating damage caused by contaminants such as bacteria, viruses, carcinogenic sources, and free radicals. (3) Regulation of other antioxidants: without glutathione, other antioxidants such as vitamin C and E do not perform their antioxidant effects properly. VC and VE are one of the traditional methods for clinically treating alcoholic liver injury. (4) Antidote: another important function of glutathione is the detoxification of exogenous chemicals (alcohol, intermediate metabolites of drugs, harmful metals, etc.).
For alcoholic liver disease, alcohol is metabolized to acetaldehyde in hepatocytes primarily by alcohol dehydrogenase in the cytosol, P450 enzymes in the microbody, and catalase in the superoxide proteasome. Acetaldehyde, a highly active substance, can react with various proteins and DNA, and also accelerates glutathione depletion, lipid peroxidation and mitochondrial damage, and has strong hepatotoxicity. Therefore, supplementation with exogenous glutathione contributes to liver function protection following alcohol consumption. During the action of alcohol dehydrogenase and acetaldehyde dehydrogenase, glutathione protects-SH group in enzyme molecule, is favorable for the exertion of enzyme activity, and can recover the activity function of-SH group in damaged enzyme molecule, so that the enzyme recovers activity again. In addition, glutathione can combine with ethanol metabolite acetaldehyde and oxygen free radical, inactivate it and accelerate free radical excretion, inhibit or reduce liver cell membrane and mitochondrial membrane peroxidized liposome formation, and protect liver cell. Meanwhile, glutathione can maintain liver protein synthesis through gamma-glutamic acid circulation. In the clinical observation of reducing glutathione for treating alcoholic liver diseases, the supplement of 1.8g of glutathione can reduce the indexes of glutamic-oxaloacetic transaminase AST and glutamic-pyruvic transaminase ALT by 60 percent, and the clinical symptoms are obviously relieved. Therefore, the alpha-lactalbumin can promote the restoration of liver functions by promoting the production of glutathione, and is beneficial to the treatment of liver diseases, particularly alcoholic liver diseases.
Meanwhile, the alpha-lactalbumin also has good repairing function on gastric mucosa. The defense mechanism of the alpha-lactalbumin affecting the gastric mucosa is mainly as follows: (1) activation of prostaglandin synthesis: prostaglandins, especially prostaglandin E2, have a strong antiulcer effect and play a key role in the gastric mucosal defense system. (2) Stimulation of mucus and bicarbonate secretion: increasing the amount of mucus in the gastric cavity prevents consumption of the gastric mucus gel layer, and reduces the damage to the gastric mucosa caused by the mechanical forces of digestion; bicarbonate ions neutralize the acid in the stomach cavity and hydrogen ions that flow back into the gastric mucus gel layer. (3) Increasing the gastric juice volume: diluting toxic factors, such as ethanol. (4) Inhibition of gastric motility (emptying and contraction): excessive contraction, i.e., increased gastric contraction, is the major pathogenic mechanism of necrosis factor and stress induced ulceration.
Gastric mucin is the major component of gastric mucus, imparting the adhesive, elastic, colloidal properties to gastric mucus. The layer of gastric mucus gel that adheres to the gastric mucosa is a barrier that protects the gastric mucosa. It coats the gastric mucosal surface, binding bicarbonate ions to neutralize hydrogen ions in the colloidal layer. Alpha-lactalbumin promotes synthesis and secretion of mucin by mucus-producing cells, causing an increase in the thickness of the mucus colloid layer, thereby increasing the content of mucin in gastric juice and gastric mucus.
Inulin, a natural water-soluble dietary fiber, is hardly hydrolyzed and digested by gastric acid and is utilized only in the colon by beneficial microorganisms, thereby improving the intestinal environment. Beneficial bacteria can be utilized in intestinal tracts, particularly bifidobacterium can be proliferated by 5-10 times, and meanwhile, harmful bacteria can be obviously reduced, so that the distribution of human flora is improved, and the health is promoted. Secondly, after the inulin is ingested, the gastrointestinal peristalsis can be enhanced, the gastrointestinal function can be improved, the digestion and the appetite can be increased, and the organism immunity can be improved. Therefore, the inulin can be used as a bifidobacterium proliferation factor, so that the composition has better functions of protecting liver and stomach.
Compared with common milk, the camel milk has better nutritive value, is rich in vitamin C, and also contains a large amount of unsaturated fatty acid, iron and vitamin B which are required by human bodies. Warm in nature, sweet in taste, cold and non-toxic. Has effects in invigorating spleen, replenishing qi, and strengthening tendons and bones.
Whey protein is a protein extracted from milk, and is called "the king of protein" due to its advantages of high purity, high absorption rate, most reasonable amino acid composition, etc. The whey protein is not only easy to digest, but also has high biological value, high digestibility, high protein efficiency ratio and high utilization rate, is a fine product in protein, is one of accepted high-quality protein supplements for human bodies, and has the content of only 0.7 percent in milk. In addition, the food derived from animal protein contains harmful substances such as excessive saturated fat and cholesterol which are harmful to human body, and excessive eating of the food can easily cause the increase of the fat and cholesterol of the human body, thereby causing the occurrence of cardiovascular diseases. Therefore, the composition can be supplemented with whey protein to prevent the above diseases while supplying high-quality protein.
Osteopontin, also known as OPN whey protein, is a glycosylated protein that is widely found in the extracellular matrix. Osteopontin is present in very high amounts in breast milk (on average about 138mg/L) and is an important immunologically active protein in breast milk. Glycosylation modification of OPN is based on O-glycans, in which the sialylation ratio is high, and may therefore also be referred to as sialoglycoproteins. The activity of osteopontin can directly reach the intestinal tract, the intestinal tract protection and barrier function is enhanced, and the whole body immune protection is realized.
Casein glycomacropeptide, also known as CGMP whey protein, has a protective effect on intestinal barriers. CGMP is used as a signal molecule to realize the regulation of the immune process of the intestinal mucosa of the organism through which immune signal pathway; CGMP has the ability to maintain intestinal mucosal immunity homeostasis. The CGMP is added into the composition, so that the composition can maintain the immunity and self-stability of intestinal mucosa of an organism, thereby effectively regulating and maintaining the internal environment of an intestinal tract and playing a role in repairing and protecting the gastrointestinal tract.
The milk mineral salt is a nutritional supplement which is prepared by taking whey as a raw material and removing protein, lactose and other components of milk basic protein and is beneficial to absorption of a human body. The milk mineral salt contains abundant minerals, mainly calcium and phosphorus, and can be used as food enhancer and nutritional supplement. In this embodiment, the milk mineral salt used is purchased from the company of Bifen, Daiichi, Inc.
The rose pollen mainly comprises carbohydrates, amino acids, proteins, vitamins, organic acids, mineral substances and the like, and also contains rich anthocyanin, flavonoid compounds, carotene, tannin and other components, wherein the most representative components are vitamin C and flavonoid compounds. Vitamin C has strong antioxidation and is helpful for eliminating free radicals in vivo, and flavonoids have remarkable effects in resisting bacteria and inflammation, reducing blood fat and lowering blood pressure, etc. Therefore, the rose pollen is added into the composition due to the effects of regulating qi and blood, soothing liver and resolving depression, so that the flavor of the composition is improved, and the protective effect on the liver can be enhanced.
The following describes in detail specific embodiments of the present invention. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
Example 1
The present embodiment provides a composition with liver and stomach protecting effects, which is prepared by the following steps:
based on 1 ton of the finished product of the composition, the following raw materials are taken:
980kg of alpha-lactalbumin; 5kg of inulin; 5kg of camel milk; 3kg of OPN whey protein; 3kg of CGMP whey protein and 2kg of milk mineral salt; 2kg of rose pollen.
And respectively sieving the raw materials by a sieve of 60-80 meshes, adding the raw materials into a mixer according to an equivalent gradual addition method, uniformly mixing, and directly packaging to obtain a finished product.
Examples 2 to 8
Compositions having liver and stomach protecting effects were prepared according to the method of example 1, based on the raw materials in table 1:
table 1 shows the proportions of the respective components in examples 2 to 8
To further illustrate the beneficial effects of the present invention, the following experiments were performed:
test example 1
1. A subject and a method:
100 patients with simple gastrointestinal ulcer of 19-61 years old (45 men and 55 women) were selected. The volunteer subject has no similar product for short term, and has no serious diseases such as gravity center, liver, kidney and hematopoietic system, etc. and mental patients. The test group and the control group were randomly divided according to body weight and body fat weight, and the test group took 45g of the product provided in example 8 of the present invention every day (taken once each time in the morning, in the middle of the morning, and at night, 15 g each time), and continuously observed for 30 days. The placebo control group was administered in the same manner as the test diet group.
2. The experimental results are as follows:
after the test subject eats the food, the gastric ulcer patient recovers the gastrointestinal function, the gastric mucosa rises obviously, the gastrointestinal function recovers to be normal, and no vomit or nausea symptom exists; the routine index of blood, stool and urine and the biochemical index of blood are not abnormal.
Experimental example two
Experimental study on composition for promoting liver function recovery after liver injury
Firstly, an experimental process:
1 materials and methods
1.1 materials: clean grade male rats 32, weighing 250g,
1.2 experimental grouping: the normal group was administered with physiological saline by the same intraperitoneal and subcutaneous route, and the control group was established as a liver injury model while the DMSO (n ═ 12) treatment group was administered daily with the liver and stomach protecting composition (n ═ 12) provided in example 8 dissolved in DMSO based on the liver injury model.
1.3 liver injury model: thioacetamide (TAA) was dissolved in physiological saline and 100mg/kg of TAA solution was intraperitoneally injected to each rat 1 time/day for 7 consecutive days.
1.4 dosing and observation treatment groups functional liver whey protein nutrition was given Id before the start of modelling, 1 dose every 24 h. TAA was injected intraperitoneally while a control group was injected subcutaneously with 0.2ml/(kg-d) DMSO' or 60mg/(kg d) of the composition for protecting liver and stomach provided in example 8 of the present invention, the solvent was 0.2ml/(kg d) DMSO, and a normal group was administered with the same intraperitoneal and subcutaneous routes as those of normal group with the same amount of physiological saline. Animals were observed 2 times daily and rat body weight and general status were recorded.
1.5 liver function assay
After stopping the injection of the TAA solution for 36h, blood was taken via the inferior vena cava under ether anesthesia and heparin was anticoagulated. The obtained blood was centrifuged at 1500rpm and immediately examined, and ALT, AST, TBIL' DBTIL, 7-GT, ALP, TBA, LDH indexes were detected by enzyme method on a Hitachi 7600 automatic analyzer.
1.6 pathological examination
Fixing the liver in 4% paraformaldehyde, conventionally embedding, flaking, HE staining, and observing the shape of the liver cell under a light microscope.
1.7 other laboratories regularly irradiated with UV light, the syringe needle and the ready-prepared drug were kept sterile to exclude the effect of infection on the experiment.
2 results
2.1 in the liver-protecting and stomach-protecting composition, the fatality rate of the liver injury of rats is reduced in the model establishment process, 4 rats in a control group die (33.33%), no death occurs in a treatment group and a normal group, and the fatality rate of the control group is obviously higher than that of the treatment group and the normal group (P < 0.05). Compared with the rats in the normal group, the rats in the control group and the treatment group have obvious weight loss (P <0.001), the weight of the normal group is obviously heavier than that of the treatment group and the control group on the 4 th day of the model (the normal group (263 +/-7.95) g, the treatment group (223.42+10.00) g, the control group (216 +/-6.95) g and P <0.001), and the weight of the treatment group is obviously higher than that of the control group (P < 0.05). At the end of the experiment (day 9), the weight of the normal group was highest (normal group (263.63 + -15.82) g, treatment group (220.17 + -12.62) g, control group (208.43 + -9.61) g, P <0.001), and the weight of the treatment group was still higher than that of the control group (P < 0.05). The rats in the control group had significantly depressed spirit compared to the treated group.
2.2 in the liver and stomach protecting composition, liver function is recovered and liver damage is recovered, the normal group and the treatment group have obvious difference (P <0.01) on indexes such as AST, TBIL, 7-GT, ALP, TBA and the like, but have no significance (P >0.05) on indexes such as ALT and LDH. There were different degrees of differences in the ALT, TBIL, ALP, TBA, LDH indices between the control and treated groups (P <0.05), but no significant differences in the AST, 7-GT indices (P > 0.05).
2.3 pathological observation after HE staining, the conditions of liver cell degeneration, necrosis, inflammatory cell infiltration and the like in the recovery period are observed, and the cell morphology of a control group, a treatment group and a normal group has no obvious pathological change except the local accidental cell degeneration change of the control group.
The experiment shows that the liver and stomach protecting composition provided by the application can obviously reduce the fatality rate of rats with liver injury. Although the weight of the rats in the treatment group is reduced compared with that in the normal group, the weight of the rats in the treatment group is obviously better than that in the control group, and the protection effect of the rats on the liver function is indirectly reflected. In the experiment, the liver function indexes of the treatment group are better than those of the control group after the liver and stomach protecting composition is used. TAA is an acute hepatotoxic compound, and after administration is stopped for 14h, liver function can be gradually recovered, which is shown by the decrease of liver injury markers such as ALT. In the experiment, the liver functions of 3 groups are recovered 36h after continuous liver injury is stopped, wherein the treatment group and the normal group have no obvious difference on ALT and LDH indexes, while the control groups ALT, TBIL, ALP, TBA and LDH are obviously higher than the treatment group, and TBA and ALT are taken as the significant indexes, namely the liver function recovery is slower than that of the treatment group, which prompts that the liver and stomach protecting composition plays a role in promoting the recovery of the liver function after the liver injury.
Previous experiments have demonstrated that whey proteins have a variety of effects, improving and reducing oxidative stress in the liver, reducing DNA damage caused by oxidation and oxidation of membrane proteins, stabilizing cell membranes, increasing the activity and expression of liver antioxidant enzymes, synergistically eliminating free radicals [ 2, 3 ], reducing the expression and activity of inflammatory mediators such as neutrophil chemokines, IL, adhesion molecules [ 4, 5 ], and combating fibroblast proliferation by affecting mRNA, EGF, nf.kb, cell cycle [ 6-8 ]. TBA, TBIL and ALT are main indexes for prompting hepatocyte damage, TBIL reflects cell damage and bilirubin metabolic disorder after hepatocyte damage, TBA reflects hepatocyte function, and ALT exists in hepatocyte, and are increased when hepatocyte is damaged.
TBA, TBIL and ALT of rats in a treatment group in the experiment are all obviously lower than those in a control group, so that the rats in the treatment group are less damaged by hepatic cells and relatively good in liver function, and the liver and stomach protecting composition provided by the application can reduce the damage of the hepatic cells, promote the recovery of the liver function after the hepatic cells are damaged and protect the damaged hepatic cells.
In addition, LDH, ALP and AST are also increased in acute liver injury, and the LDH, ALP and AST results of the experiment also reflect the liver protection effect of the liver and stomach protection composition. Oxidative stress, inflammatory reaction and the like are initial reasons causing liver cell damage, the liver damage of a treatment group rarely reflects the antioxidant stress and the anti-inflammatory action of the liver and stomach protecting composition, and the action mechanism is consistent with the results of reducing the liver damage and promoting the recovery of the liver function.
Finally, it should be noted that: the above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. The composition with the effects of protecting liver and stomach is characterized by mainly comprising the following raw materials in parts by weight:
35-98 parts of alpha-lactalbumin, 0.5-40 parts of inulin, 0.5-10 parts of camel milk, 0.3-5 parts of osteopontin and 0.3-4 parts of casein glycomacropeptide.
2. The composition according to claim 1, which is characterized by mainly comprising the following raw materials in parts by weight:
40-95 parts of alpha-lactalbumin, 2-30 parts of inulin, 2-8 parts of camel milk, 0.5-2 parts of osteopontin and 0.5-2 parts of casein glycomacropeptide.
3. The composition according to claim 2, which is characterized by mainly comprising the following raw materials in parts by weight:
90 parts of alpha-lactalbumin, 5 parts of inulin, 3 parts of camel milk, 1 part of osteopontin and 1 part of casein glycomacropeptide.
4. The composition of any one of claims 1 to 3, wherein the composition further comprises milk mineral salts and rose pollen.
5. The composition of claim 4, wherein the milk mineral salt is 0.2 to 3 parts by weight and the rose pollen is 0.2 to 3 parts by weight.
6. The composition according to claim 5, wherein the milk mineral salt is 0.6 to 1.5 parts by weight, and the rose pollen is 0.2 to 1.5 parts by weight.
7. A method of preparing a composition according to any one of claims 1 to 6, comprising:
mixing the alpha-lactalbumin, the inulin, the camel milk, the osteopontin and the casein glycomacropeptide according to the weight parts.
8. The method of claim 7, further comprising the step of sieving the alpha-lactalbumin, inulin, camel milk, osteopontin, and casein glycomacropeptide with a 60-80 mesh sieve before mixing.
9. Use of the composition according to any one of claims 1 to 6 for the preparation of a health product for the prevention or treatment of liver damage, gastric ulcer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210199923.9A CN114557452A (en) | 2022-03-02 | 2022-03-02 | Composition with liver and stomach protecting effects and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210199923.9A CN114557452A (en) | 2022-03-02 | 2022-03-02 | Composition with liver and stomach protecting effects and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114557452A true CN114557452A (en) | 2022-05-31 |
Family
ID=81716594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210199923.9A Pending CN114557452A (en) | 2022-03-02 | 2022-03-02 | Composition with liver and stomach protecting effects and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114557452A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101283809A (en) * | 2007-04-11 | 2008-10-15 | 厦门金日制药有限公司 | High nutrient protein powder for strengthening the human immunologic function |
| WO2010123351A1 (en) * | 2009-04-20 | 2010-10-28 | Friesland Brands B.V. | Satiety inducing milk product |
| CN107668208A (en) * | 2017-11-13 | 2018-02-09 | 海普诺凯营养品有限公司 | A kind of formula milk for promoting intestinal health |
| CN108617779A (en) * | 2018-03-29 | 2018-10-09 | 新疆旺源生物科技集团有限公司 | A kind of hunchbacked milk composition having auxiliary protection function to chemical damage |
| CN109906040A (en) * | 2016-07-06 | 2019-06-18 | 积木营养品有限公司 | Nutritional formulas |
| CN111447842A (en) * | 2017-12-22 | 2020-07-24 | 雀巢产品有限公司 | Extract and use thereof |
| CN112841316A (en) * | 2021-02-03 | 2021-05-28 | 合生元（广州）健康产品有限公司 | Personalized nutritional composition comprising oligosaccharides |
| CN113841739A (en) * | 2021-09-29 | 2021-12-28 | 陕西金雪莲丝路乳业集团有限公司 | Formula and preparation method of milk powder for conditioning blood sugar, intestines and stomach and hypertension, hyperlipidemia and hyperglycemia population |
-
2022
- 2022-03-02 CN CN202210199923.9A patent/CN114557452A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101283809A (en) * | 2007-04-11 | 2008-10-15 | 厦门金日制药有限公司 | High nutrient protein powder for strengthening the human immunologic function |
| WO2010123351A1 (en) * | 2009-04-20 | 2010-10-28 | Friesland Brands B.V. | Satiety inducing milk product |
| CN109906040A (en) * | 2016-07-06 | 2019-06-18 | 积木营养品有限公司 | Nutritional formulas |
| CN107668208A (en) * | 2017-11-13 | 2018-02-09 | 海普诺凯营养品有限公司 | A kind of formula milk for promoting intestinal health |
| CN111447842A (en) * | 2017-12-22 | 2020-07-24 | 雀巢产品有限公司 | Extract and use thereof |
| CN108617779A (en) * | 2018-03-29 | 2018-10-09 | 新疆旺源生物科技集团有限公司 | A kind of hunchbacked milk composition having auxiliary protection function to chemical damage |
| CN112841316A (en) * | 2021-02-03 | 2021-05-28 | 合生元（广州）健康产品有限公司 | Personalized nutritional composition comprising oligosaccharides |
| CN113841739A (en) * | 2021-09-29 | 2021-12-28 | 陕西金雪莲丝路乳业集团有限公司 | Formula and preparation method of milk powder for conditioning blood sugar, intestines and stomach and hypertension, hyperlipidemia and hyperglycemia population |
Non-Patent Citations (2)
| Title |
|---|
| 徐德洲;陆罗定;杨明晶;施伟庆;: "驼奶对急性酒精肝损伤的辅助保护作用", 江苏预防医学, no. 03 * |
| 王蓓: "牛乳中乳清蛋白质的功能活性研究进展", 中国食品学报, vol. 21, no. 9, pages 1 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2255818B1 (en) | Oral or enteral composition useful for recovery of physical functions | |
| US20100190708A1 (en) | Composition for amelioration of body lipid | |
| CN108685100B (en) | Formula and preparation method of composite short peptide powder | |
| CN101715913B (en) | Capsule for regulating blood fat and production process thereof | |
| CN112772813A (en) | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof | |
| WO2011047518A1 (en) | Enteral nutrition comprising marine bioactive polysaccharide, preparation method and use thereof | |
| CN110651830A (en) | Modified milk powder for improving sleep and preparation method thereof | |
| CN103006709B (en) | Bee-pollen buccal tablet for preventing and treating alcoholic fatty liver | |
| CN104998252B (en) | One kind mends iron blood-enriching oral liquid and preparation method thereof | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| JP5383244B2 (en) | Nutritional agent suitable for improving symptoms or nutritional status of cancer patients | |
| CN114557452A (en) | Composition with liver and stomach protecting effects and preparation method and application thereof | |
| CN101703497A (en) | Application of Chlorogenic acid in preparing drug having protection and restoration functions on spleen hematopoietic stem cell injuries | |
| CN1252231A (en) | Hemoglobin food series and its production process | |
| CN114868890A (en) | Multi-vitamin nutrient formula suitable for tumor patients | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity | |
| JPS6147418A (en) | Drug for promoting and keeping health containing chondroitin sulfuric acid and hyaluronic acid | |
| CN105995971A (en) | Nutritional liquid food for promoting diabetes recovery and preparation method thereof | |
| WO2016206363A1 (en) | Use of jilin ginseng oligopeptide in preparation of anti-oxidant food product or health care food product | |
| KR101908850B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Anti-Obesity and the Method of Making the Same | |
| CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine | |
| CN111686236B (en) | Capsule for dispelling effects of alcohol, protecting liver and protecting brain | |
| CN117431287A (en) | Preparation method for preparing donkey-hide gelatin peptide-iron chelate by enzymatic hydrolysis of donkey-hide gelatin | |
| CN1806576B (en) | Method for preparing kidney-replenishing fatigue-alleviating yoghourt with micron antler powder, gadol powder, bee pollen, cactus powder and dodder powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |